Targeted Therapies for Cancer

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary antibody-drug conjugate (ADC) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

Product Pipeline

The US Food and Drug Administration (FDA) has granted orphan drug designation to ImmunoGen’s experimental ADC IMGN853 for the treatment of ovarian cancer.

Learn more about our pipeline.

ImmunoGen, Inc. one of The Boston Globe’s Top Places to Work 2014 – also recognized in 2013, 2011 

TPTW 2014

Our Antibody-Drug Conjugate (ADC) Technology

  • Roche’s Kadcyla® is the first marketed ADC with our technology.
  • Based on its work with Kadcyla, ImmunoGen was selected by The Boston Globe as a "Game Changer" – a local organization that is helping to make Massachusetts a leader in innovation.
  • Other partners developing ADCs with our technology are Amgen, Bayer HealthCare, Biotest, Lilly, Novartis and Sanofi.    

ImmunoGen News

Read our releases...